Artículos de revistas
Progression Of Liver Fibrosis In Blood Donors Infected With Hepatitis C Virus
Registro en:
Romanian Journal Of Gastroenterology. , v. 13, n. 4, p. 291 - 297, 2004.
12214167
2-s2.0-11844289557
Autor
Silva G.F.
Coelho K.I.R.
Nishimura N.F.
Soares E.C.
Institución
Resumen
Background/Aims. Chronic hepatitis by HCV is progressive towards cirrhosis, with variable rate. We evaluated the rate of fibrosis progression (RFP), risk factors associated with advanced fibrosis (F3 and F4), and estimated the evolution time to cirrhosis. Methods. We transversely selected 142 blood donors infected only with HCV, with a known route of infection, submitted to liver biopsy at admission. RFP= ratio between stage of fibrosis (METAVIR)/estimated duration of infection in years. Non-parametric tests and logistic regression analysis, with significance level of 5% were used. Results. Median RFP was 0.086 U/year (0.05 - 0.142). Ten patients had F4 and 25 had F3. Median RFP values were significantly different (p=0.001) from one age group at contamination to the others and ALT and AST levels. There were no differences in the expected evolution to cirrhosis between intermediate fibrosers (F2) and the rapid fibrosers (F3 and F4). The independent variables associated with advanced fibrosis were ALT (OR 7.2) and GGT (OR 6.4) and age at inclusion (OR 1.12). Conclusion. This study suggests that RFP is extremely variable, it is exponential with age, and mainly influenced by host characteristics, especially age at contamination and possibly ethnical group. These asymptomatic patients had high percentage of fibrosis F2, F3 and F4. 13 4 291 297 Seeff, L.B., Natural history of hepatitis C (1997) Hepatology, 26 (SUPPL. 1), pp. S21-S28 Alter, H.J., Seeff, L.B., Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome (2000) Semin Liver Dis, 20, pp. 17-35 Di Bisceglie, A.M., Hepatitis C and hepatocellular carcinoma (1997) Hepatology, 26 (SUPPL. 1), pp. S34-S38 EASL: International consensus conference on hepatitis C. Consensus statement (1999) J Hepatol, 30, pp. 956-961 Fattovich, G., Giustina, G., Degos, F., Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients (1997) Gastroenterology, 112, pp. 463-472 Serfaty, L., Aumaitre, H., Chazouilleres, O., Determinants of outcome of compensated hepatitis C virus-related cirrhosis (1998) Hepatology, 27, pp. 1435-1440 Hu, K.-Q., Tong, M.J., The long-term outcomes of patients with compensated hepatitis C virus related cirrhosis and history of parenteral exposure in the United States (1999) Hepatology, 29, pp. 1311-1316 Poynard, T., Bedossa, P., Opolon, P., Natural history of liver fibrosis progression in patients with chronic hepatitis C (1997) Lancet, 349, pp. 825-832 Freeman, A.J., Dore, G.J., Law, M.G., Estimating progression to cirrhosis in chronic hepatitis C virus infection (2001) Hepatology, 34, pp. 809-816 Poynard, T., Ratziu, V., Benmanov, Y., DiMartino, V., Bedossa, P., Opolon, P., Fibrosis in the patients with chronic hepatitis C, detection and significance (2000) Semin Liver Dis, 20, pp. 47-55 Shivakumar, C., Jacob, G., Predictors of liver-related complications in patients with chronic hepatitis C (2000) Ann Med, 32, pp. 588-591 Stuyver, L., Wyseur, A., Van Arnhem, W., Hernandez, F., Maertens, G., Second generation line probe assay for hepatitis C virus genotyping (1996) J Clin Microbiol, 34, pp. 2259-2266 Silva, G.F., Nishimura, N.F., Caramori, C., Soares, E.C., Influence of a regional habit on the hepatitis C virus infection: The role of Gluconergan® (2001) Hepatology, 34, pp. 574A Seeff, L.B., Hollinger, F.B., Alter, H.J., Long-term mortality and morbidity of transfusion-associated Non-A, Non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute Collaborative study (2001) Hepatology, 33, pp. 455-463 Seeff, L.B., Natural history of chronic hepatitis C (2002) Hepatology, 36, pp. S35-S46 Sobesky, R., Mathurin, P., Charlotte, F., Modeling the impact of interferon alpha treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view (1999) Gastroenterology, 116, pp. 378-386 Berenguer, M., Ferrel, L., Watson, J., HCV-related fibrosis progression following liver transplantation: Increase in recent years (2000) J Hepatol, 32, pp. 673-684 Tanaka, E., Kiyosawa, K., Natural history of acute hepatitis C (2000) J Gastroenterol Hepatol, 15 (SUPPL.), pp. E97-E104 Poynard, T., McHutchison, J., Manns, M., Impact of pegylated interferon alpha-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C (2002) Gastroenterology, 122, pp. 1303-1313 Kim, W., Gross Jr., J.B., Poterucha, J.J., Locke, G.R., Dickson, R., Outcome of hospital care of liver disease associated with hepatitis C in the United States (2001) Hepatology, 33, pp. 201-206 Ostapowicz, G., Watson, K.J., Locarnini, S.A., Desmond, P.V., Role of alcohol in the progression of liver disease caused by hepatitis C virus infection (1998) Hepatology, 27, pp. 1730-1735 Bonacini, M., Groshen, S., Yu, M.C., Govindarajan, S., Lindsay, K.L., Chronic hepatitis C in ethnic minority patients evaluated in Los Angeles County (2001) Am J Gastroenterol, 96, pp. 2438-2441 Khan, M.H., Farrell, G.C., Byth, K., Which patients with hepatitis C develop liver complications? (2000) Hepatology, 31, pp. 513-520 Kage, M., Shimamatu, K., Nakashima, E., Kojiro, M., Inoue, O., Yano, M., Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C: Morphometric analysis of repeated biopsies (1997) Hepatology, 25, pp. 1028-1031 Matsumura, H., Moriyama, M., Goto, I., Tanaka Nokubo, H., Arakawa, Y., Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C: A study of 527 patients at one stablishment (2000) J Viral Hepat, 7, pp. 268-275 Adinolfi, L.E., Gambardella, M., Andreana, A., Tripodi, M.F., Utili, R., Ruggiero, G., Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity (2001) Hepatology, 33, pp. 1358-1364 Monto, A., Alonzo, J., Watson, J.J., Grunfeld, C., Wright, T.L., Steatosis in chronic hepatitis C: Relative contributions of obesity, diabetes mellitus, and alcohol (2002) Hepatology, 36, pp. 729-736 Mathurin, P., Moussalli, J., Cadranel, J.F., Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity (1998) Hepatology, 27, pp. 868-872 Jamal, M.M., Soni, A., Quinn, P.G., Wheeler, D.E., Arora, S., Johnston, D.E., Clinical features of hepatitis C infected patients with persistently normal alanine transaminase levels in the southwestern United States (1999) Hepatology, 30, pp. 1307-1311 Hervé, S., Savoye, G., Riachi, G., Chronic hepatitis C with normal or abnormal aminotransferase levels: Is it the same entity? (2001) Eur J Gastroenterol Hepatol, 13, pp. 495-500 Poynard, T., Ratziu, V., Charlotte, F., Goodman, Z., McHutchison, J., Albrecht, J., Rates and risk factors of liver fibrosis progression in patients, with chronic hepatitis C (2001) J Hepatol, 34